Background: The incidence of type 2 diabetes (T2D) in children and adolescents is increasing worldwide, largely driven by the obesity epidemic. Young-onset T2D is associated with rapid disease progression and an early risk of cardiovascular and microvascular complications.
Objective: To describe the clinical, anthropometric, and cardiometabolic characteristics of young patients with T2D and to assess their early cardiovascular risk profile, with particular attention to plasma homocysteine levels.
Methods: This single-center, cross-sectional observational study included 35 young patients with T2D (aged 12–28 years) followed at a tertiary pediatric endocrinology center. Demographic, anthropometric, and biochemical data were collected, including body mass index (BMI), glycated hemoglobin (HbA1c), lipid profile, plasma homocysteine levels, and diabetes-related complications. Hyperhomocysteinemia was defined as a plasma homocysteine concentration >15 μmol/L. Data were analyzed using descriptive statistics.
Results: The mean age at diagnosis was 13.0 ± 3.5 years. Most patients were overweight or obese, with a mean BMI of 31.5 kg/m². Glycemic control was suboptimal, with a mean HbA1c of 8.05%. Lipid analysis revealed normal total cholesterol (1.60 g/L) and acceptable LDL cholesterol (0.83 g/L), alongside elevated triglycerides (1.47 g/L), consistent with an adverse cardiometabolic profile. No documented retinopathy or neuropathy was observed, whereas early nephropathy (microalbuminuria) was frequently detected. Cardiac abnormalities were identified in 7% of evaluated patients, and four female patients met the diagnostic criteria for polycystic ovary syndrome (PCOS). Plasma homocysteine was assessed in 17 patients, with hyperhomocysteinemia (>15 μmol/L) detected in 64.7% (11/17) and a mean concentration of 15.08 ± 6.89 μmol/L (range, 6–32 μmol/L).
Conclusions: Young-onset T2D is characterized by obesity, inadequate glycemic control, and early cardiometabolic abnormalities despite the absence of established retinopathy or neuropathy. Hyperhomocysteinemia may serve as an additional cardiovascular risk marker in this population and warrants further investigation. Early multidisciplinary intervention is essential to reduce long-term morbidity.

